J Cancer 2018; 9(2):263-268. doi:10.7150/jca.20059

Review

Cancer vaccine: learning lessons from immune checkpoint inhibitors

ZhenLong Ye, Qiming Qian, HuaJun Jin, QiJun Qian

Shanghai Engineering Research Center for Cell Therapy, 75 Qianyang Road, Shanghai 201805, China.

Abstract

Cancer vaccines have been exclusively studied all through the past decades, and have made exceptional achievements in cancer treatment. Few cancer vaccines have been approved by the US Food and Drug Administration (FDA), for instance, Provenge, which was approved for the treatment of prostate carcinoma in 2012. Moreover, more recently, T-VEC got approval for the treatment of melanoma. While, the overall therapeutic effects of cancer vaccines have been taken into consideration as below expectations, low antigenicity of targeting antigen and tumor heterogeneity are the two key limiting barriers encountered by the cancer vaccines. Nonetheless, recent developments in cancer immune-therapies together with associated technologies, for instance the unparalleled achievements bagged by immune checkpoint inhibitor based therapies and neo-antigen identification tools, envisage potential improvements in cancer vaccines in respect to the treatments of malignancies. This review brings forth measures for the purpose of refining therapeutic cancer vaccines by learning lessons from the success of PD-1 inhibitor based immune-therapies.

Keywords: Cancer vaccine, immune checkpoint inhibitor, PD-1, combination therapy, immunotherapy

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Ye Z, Qian Q, Jin H, Qian Q. Cancer vaccine: learning lessons from immune checkpoint inhibitors. J Cancer 2018; 9(2):263-268. doi:10.7150/jca.20059. Available from http://www.jcancer.org/v09p0263.htm